Related Experiment Video
Updated: May 29, 2026

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model
Published on: November 4, 2025
Auxological criteria for treating children with idiopathic short stature
1Servizio di Endocrinologia Pediatrica, Ospedale Microcitemico - ASL Cagliari, Cagliari, Italy.
Insights
Biosynthetic growth hormone (GH) treatment can increase adult height in children with idiopathic short stature (ISS). However, predicting individual responses to GH therapy remains challenging, necessitating careful patient selection.
Area of Science:
- Pediatrics
- Endocrinology
- Growth Disorders
Background:
- Children with idiopathic short stature (ISS) often fail to reach their genetic target adult height.
- Biosynthetic growth hormone (GH) was approved in 2003 for specific ISS cases unlikely to achieve normal adult height.
- While GH therapy increases adult height, predicting individual patient response is complex.
Purpose of the Study:
- To review the efficacy and predictability of growth hormone (GH) treatment in children with idiopathic short stature (ISS).
- To identify key factors influencing treatment outcomes for ISS patients.
Main Methods:
- Analysis of auxological variables including age, height at treatment initiation, bone age delay, predicted height, and height velocity.
- Multivariate analyses were employed to predict treatment outcomes.
- Evaluation of first-year responsiveness to GH therapy.
Main Results:
- Controlled studies demonstrate a significant increase in adult height with GH treatment for ISS.
- Individual responses to GH therapy exhibit considerable variability.
- Predicting the precise response to GH treatment remains a challenge.
Conclusions:
- Growth hormone (GH) therapy offers a substantial benefit for increasing adult height in children with idiopathic short stature (ISS).
- Auxological variables and growth pattern analysis are crucial for guiding treatment decisions.
- Careful patient selection based on predicted height and growth patterns is essential for optimizing GH therapy outcomes.
Abstract:
Children with idiopathic short stature (ISS) may not reach an adult height within their genetic target. In 2003, the United States Food and Drug Administration approved biosynthetic growth hormone (GH) for the treatment of children with ISS whose heights exceeded 2.25 standard deviation scores below the mean and who were considered unlikely to reach a normal adult height. Results of controlled studies have shown that, although GH treatment leads to a substantial increase in adult height, the individual response to therapy is difficult to predict. A number of auxological variables (i.e., age and height at start of treatment, bone age delay, mean predicted height, height velocity and first-year responsiveness) are used in multivariate analyses to predict outcomes. Estimation of target height, predicted adult height and pattern of growth should guide the decision to treat a child with ISS.
Related Concept Videos
Nature and Nurture
Criteria for Causality: Bradford Hill Criteria - II
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Polygenic Traits
Pharmacokinetics in Pediatric Patients: Drug Excretion

